Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston

Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) ("Hydreight" or the "Company"), a healthcare technology company operating a nationwide physician-supervised healthcare platform with a network of more than 300 licensed physicians, more than 3,000 licensed nurses, and pharmacy partners serving all 50 U.S. states, is pleased to announce that it has been invited to participate in Canaccord Genuity's 46th Annual Growth Conference, taking place August 11–13, 2026, at the InterContinental Boston in Boston, Massachusetts.

The Canaccord Genuity Growth Conference is one of North America's premier institutional investor conferences, bringing together leading public and private growth companies with institutional investors from around the world across the technology, healthcare & life sciences, sustainability, industrials, and consumer sectors.

Hydreight will be represented by Shane Madden, Chief Executive Officer, and Shafin Diamond Tejani, Board Chair, who will meet with institutional investors throughout the conference to discuss the Company's recent operating progress, expanding healthcare ecosystem, and long-term growth strategy.

Recent Corporate Highlights Reported record first quarter 2026 revenue of $24.9 million, representing 449% year-over-year growth, Adjusted EBITDA of $3.3 million and $32 million in working capital.

Expanded the VSDHOne ecosystem to more than 12,000 licenses sold, compared to approximately 3,000 licenses at the end of 2025.

Expanded its nationwide healthcare network to include more than 300 licensed physicians, more than 3,000 licensed nurses, nationwide pharmacy partnerships, and operations across all 50 U.S. states.

Expanded its portfolio to more than 45 physician-supervised healthcare products and programs, including GLP-1s, peptides, hormone health, weight management, wellness, diagnostics, and preventative healthcare offerings.

Recently provided a business update outlining the Company's peptide healthcare platform following the U.S. Food and Drug Administration's recent advisory committee recommendations related to certain compounded peptide substances.

Maintained a strong cash position to support continued organic growth, platform expansion, and strategic opportunities.

Management expects discussions with investors to focus on the Company's continued operating momentum, expansion of the VSDHOne platform, peptide healthcare initiatives, and long-term growth strategy.

The Company encourages institutional investors interested in meeting with management during the conference to contact their Canaccord Genuity representative.

On behalf of the Board of Directors Shane Madden Director and Chief Executive Officer Hydreight Technologies Inc.

About Hydreight Technologies Inc. Hydreight Technologies Inc. is building a nationwide physician-supervised healthcare platform across the United States. Its proprietary technology platform supports a network of more than 300 licensed physicians, more than 3,000 licensed nurses, and a nationwide pharmacy network serving all 50 U.S. states. The platform includes integrated telehealth, compliance, medical documentation, scheduling, pharmacy, billing, and patient engagement tools that enable licensed healthcare professionals and healthcare brands to deliver compliant healthcare services across the country. Through its infrastructure and VSD...